What is pertuzumab?

Breast cancer is the most common malignant tumor among women. Among patients with early-stage HER2-positive breast cancer who receive trastuzumab combined with chemotherapy, approximately one-quarter still experience disease recurrence or death within 10–11 years. The rates of recurrence and mortality are even higher among high-risk early-stage breast cancer patients. So, what exactly is pertuzumab? We will address this question below.

What is pertuzumab?

Pertuzumab injection is a novel anti-HER2 therapeutic agent developed by Roche. It exerts its anti-HER2 effects by inhibiting both HER2 heterodimerization and homodimerization. Global pivotal Phase III adjuvant therapy trials demonstrated that, compared with the current standard treatment—trastuzumab plus chemotherapy—pertuzumab in combination with trastuzumab and chemotherapy significantly improves invasive disease-free survival (iDFS) in patients with high-risk, early-stage HER2-positive breast cancer, with manageable adverse reactions.

Given its favorable clinical benefit–risk profile, the National Medical Products Administration (NMPA) of China approved the import registration of pertuzumab on December 17, 2018, for use in combination with trastuzumab and chemotherapy as adjuvant therapy in patients with high-risk, early-stage HER2-positive breast cancer.

The above regimen is provided for reference only. Specific usage should follow the product labeling or be administered under the guidance of a physician at an authorized medical institution.

We hope this information is helpful to you.